Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2017

View Archived Issues

FDA awards orphan drug designation to Cascadian's tucatinib

AzurRx reports initial data from ongoing phase IIa trial of MS-1819-SD

Synergys Biotherapeutics receives grant to support SYN-001 development

Diamyd to design first clinical trial of Remygen

NIDA grant supports Camino Pharma's development of compounds for substance use disorders

New lung cancer study to utilize Inivata's InVision liquid biopsy platform

Safety explored in first-in-human study of KHK-4083, a monoclonal antibody targeting OX40

Eidos Therapeutics doses first cohort in AG-10 phase I study

Topline results from phase I/II study of SciFluor's SF-0166 for DME

Inhaled sodium cromoglycate formulation PA-101 reduces cough in IPF patients

Villin-1 as a biomarker of intestinal ischemia reperfusion injury

Achaogen awarded contract for development of C-Scape

Protagenic Therapeutics' PT-00114 shows efficacy in animal models

GlaxoSmithKline divulges CD73 inhibitors

FDA gives Emergency Use Authorization to Chembio for DPP Zika system test

Merck & Co. patents novel monobactam derivatives for bacterial infections

Raze Therapeutics identifies 3-PGDH inhibitors

Global Alliance for TB Drug Development patents compounds for tuberculosis

New York University discloses Wnt signaling inhibitors

FDA grants orphan drug designation to rimeporide for Duchenne muscular dystrophy

SI-613 begins phase II trial in Japan for enthesopathy

FDA approves Verzenio in breast cancer

Japanese orphan drug designation for olaparib for BRCA-positive breast cancer

First subject enrolled in phase III study of TRC-101 in chronic kidney disease

Quidel announces progress in acquisition of Alere's BNP business

FDA grants priority review to Amitiza sNDA for pediatric functional constipation

TLR3 identified as novel target for preventing cardiac ischemia reperfusion injury

Phase Ib data do not support progression of PRX-003 for psoriasis

U.S. contract supports progression of InBios point-of-care diagnostic test for B. anthracis

Zynerba reports promising data from phase II trial of ZYN-002 for fragile X syndrome

Curemark completes enrollment in phase III trial of CM-AT in autism

FDA grants priority review to Linhaliq NDA

FDA priority review for Perjeta sBLA for adjuvant treatment of HER2-positive early breast cancer

NIAID grant supports development of thermostable trivalent Ebola vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...